Literature DB >> 29172902

Insulin-like growth factor type 1 concentrations in hyperthyroid cats before and after treatment with thiamazole.

Daphné Rochel1, Myriam Burger1, Patrick Nguyen1,2, Laetitia Jaillardon1,2.   

Abstract

Objectives The aim of this study was to evaluate changes in circulating insulin-like growth factor type 1 (IGF-1) concentrations in hyperthyroid cats, before and after thiamazole treatment. Methods Thirty-four hyperthyroid cats were retrospectively included. Plasma free thyroxine (fT4) and IGF-1 concentrations were measured at diagnosis and 3 months after initiating antithyroid drug therapy. Results Median fT4 significantly decreased ( P <0.001) after treatment (from 78 pmol/l [range 43-122 pmol/l] to 31 pmol/l [range below assay limit of detection to 88 pmol/l]), whereas IGF-1 values significantly increased ( P <0.001) after treatment (from 117 ng/ml [33-341 ng/ml] to 221 ng/ml [36-865 ng/ml]). fT4 and IGF-1 concentrations were significantly negatively correlated both at diagnosis (r = -0.43, P = 0.01) and after treatment (r = -0.51, P = 0.002). Conclusions and relevance In cats, IGF-1 concentrations appear to be inversely proportional to the severity of hyperthyroidism and significantly increase after treatment with thiamazole.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29172902     DOI: 10.1177/1098612X17694735

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  2 in total

1.  Teprotumumab-associated chronic hearing loss screening and proposed treatments.

Authors:  Audrey Chow; Rona Z Silkiss
Journal:  BMJ Case Rep       Date:  2022-04-13

2.  Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chiao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.